$290 Million is the total value of Avoro Capital Advisors LLC's 31 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 25.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Sell | MIRATI THERAPEUTICS INC. | $39,755,000 | -20.5% | 1,258,055 | -13.4% | 13.70% | +5.3% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $34,101,000 | -42.6% | 3,515,611 | -17.3% | 11.75% | -24.0% |
| LJPC | Sell | LA JOLLA PHARMACEUTICAL CO. | $21,173,000 | -5.3% | 784,199 | -2.5% | 7.29% | +25.5% |
| PTX | Sell | PERNIX THERAPEUTICS HOLDINGS | $15,178,000 | -20.0% | 5,144,916 | -14.3% | 5.23% | +6.0% |
| DERM | Sell | DERMIRA INC | $12,285,000 | +44.9% | 354,950 | -2.3% | 4.23% | +92.0% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $11,738,000 | -51.0% | 1,260,809 | -40.7% | 4.04% | -35.1% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $9,987,000 | -44.7% | 1,146,579 | -46.7% | 3.44% | -26.7% |
| ONTY | Sell | ONCOTHYREON INC | $9,144,000 | -39.4% | 4,119,072 | -25.2% | 3.15% | -19.7% |
| Sell | NEURODERM LTD. | $8,866,000 | -61.1% | 520,022 | -52.9% | 3.05% | -48.5% | |
| NK | Sell | NANTKWEST- INC | $8,828,000 | +20.9% | 599,287 | -17.8% | 3.04% | +60.2% |
| AEGR | Sell | AEGERION PHARMACEUTICALS INC | $7,405,000 | -32.5% | 733,125 | -9.1% | 2.55% | -10.5% |
| AXGT | Sell | AXOVANT SCIENCES LTD. | $5,536,000 | +5.4% | 307,070 | -24.5% | 1.91% | +39.7% |
| VCYT | Sell | VERACYTE INC | $5,338,000 | +47.4% | 741,353 | -4.0% | 1.84% | +95.2% |
| EGLTQ | Sell | EGALET CORPORATION. | $4,767,000 | -17.9% | 432,606 | -1.8% | 1.64% | +8.7% |
| INNL | Sell | INNOCOLL AGsponsored adr | $4,164,000 | -33.8% | 501,722 | -0.1% | 1.43% | -12.3% |
| Sell | TRILLIUM THERAPEUTICS INC | $3,199,000 | -4.5% | 253,697 | -0.5% | 1.10% | +26.5% | |
| TNXP | Sell | TONIX PHARMACEUTICALS HLDG | $2,610,000 | +20.3% | 340,300 | -17.1% | 0.90% | +59.4% |
| ALQA | Sell | ALLIQUA BIOMEDICAL INC | $1,796,000 | -33.4% | 839,100 | -1.3% | 0.62% | -11.7% |
| SRPT | Sell | SAREPTA THERAPEUTICS -INCcall | $626,000 | -49.4% | 47,300 | -73.5% | 0.22% | -32.9% |
| CBIO | Sell | CATALYST BIOSCIENCES INC. | $224,000 | -42.7% | 71,500 | -14.8% | 0.08% | -24.5% |
| KITE | Exit | KITE PHARMA INC.put | $0 | – | -26,000 | -100.0% | -0.03% | – |
| HRTX | Exit | HERON THERAPEUTICS INCcall | $0 | – | -500,000 | -100.0% | -0.04% | – |
| HTBX | Exit | HEAT BIOLOGICS INC | $0 | – | -341,064 | -100.0% | -0.41% | – |
| IWM | Exit | ISHARES RUSSELL 2000 ETFput | $0 | – | -1,280,000 | -100.0% | -1.29% | – |
| SPPI | Exit | SPECTRUM PHARMACEUTICALS INC | $0 | – | -1,315,600 | -100.0% | -2.04% | – |
| IG | Exit | IGI LABORATORIES INC | $0 | – | -1,779,782 | -100.0% | -3.03% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -581,900 | -100.0% | -5.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC. | 39 | Q2 2024 | 17.9% |
| MIRATI THERAPEUTICS INC. | 36 | Q4 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 34 | Q2 2024 | 8.0% |
| SAREPTA THERAPUTICS INC | 31 | Q2 2024 | 14.8% |
| ASCENDIS PHARMA | 31 | Q2 2024 | 9.1% |
| ARGENX SE | 29 | Q2 2024 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 29 | Q2 2024 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 26 | Q4 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 25 | Q2 2024 | 7.7% |
| XENON PHARMACEUTICALS INC | 25 | Q2 2024 | 3.6% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Spyre Therapeutics, Inc. | April 23, 2024 | 1,839,138 | 5.1% |
| AMICUS THERAPEUTICS, INC. | February 14, 2024 | 27,400,000 | 9.3% |
| Apellis Pharmaceuticals, Inc. | February 14, 2024 | 13,411,111 | 9.9% |
| Ascendis Pharma A/S | February 14, 2024 | 3,755,555 | 6.5% |
| BIOCRYST PHARMACEUTICALS INC | February 14, 2024 | 13,050,000 | 6.4% |
| CymaBay Therapeutics, Inc. | February 14, 2024 | 16,337,739 | 10.0% |
| IO Biotech, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Krystal Biotech, Inc. | February 14, 2024 | 2,565,555 | 9.1% |
| Kymera Therapeutics, Inc. | February 14, 2024 | 3,775,000 | 6.8% |
| MADRIGAL PHARMACEUTICALS, INC. | February 14, 2024 | 2,288,888 | 9.9% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-27 |
| 13F-HR | 2024-08-14 |
| 4 | 2024-06-14 |
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.